The name change reflects the company leadership position with its cryptocurrency treasury reserve strategy focused on the media threshing token
The company starts to negotiate on the Nasdaq under the symbol “hypd” from July 3
Announcement also the official launch of the Kinetiq x Hyperion validator
Laguna Hills, California, July 02, 2025 (Globe Newswire) – Eyenovia, Inc. (Nasdaq: Eyen) (“Eyenovia” or “Company”), a pioneer in ophthalmic technologies and the first public public publicly publicly to build a strategic treasure of Treasury of THRESHINGThe native token of the hyperliquid protocol, announced today that it returned and changed its business name in Hyperion DEFI, Inc., in addition to the change of name, the actions of the company will begin to negotiate under the new symbol of Ticker “Hypd” on the Nasdaq capital market at the start of the negotiation on July 3, 2025.
The name change reflects the recent launch by the company of its cryptocurrency reserve reserve strategy focused on the media threshing token, originally from the exchange of decentralized digital assets and the blockchain of layer 1, hyperliquid.
“Our change of business name in Hyperion DEFI, Inc. reflects our new vision for the company and represents the next important step in the evolution of our cryptocurrency cash reserve strategy,” said Michael Rowe, CEO of Eyenovia / Hyperion Defi, Inc. “in particular” of the media on a global scale and the largest treasure based on cryptocurrencies
“As Keats poem reflects the same name that tells of the defeat of the Titans in the hands of the Olympians,” Hyperion “evokes themes of changing order,” added Hyunsu Jung, director of investments. “In this case, the emergence of blockchain technology not only defies the existing financial infrastructures, but also the trade in cryptocurrency centralized.
As part of this announcement, the co-marked validator of Hyperion Defi “Kinetiq x Hyperion” is officially live. The company began to mark out its planking media operations to generate a return and further prepare for its onchain engagement strategies.
The CUSIP number for the company’s ordinary actions is not affected by the name change.
About Hyperion Defi, Inc.
Hyperion DEFI, Inc. is the first company listed on the public stock market to build a long -term strategic treasure of the native token of hyperliquid, media threshing. The company focuses on the supply of its shareholders, a simplified access to the hyperliquid ecosystem, one of the fastest and highest revenue blockchains in the world. The shareholders benefit from an exposure gradually aggravating media, both from its native return and additional income generated by its unique chain utility.
Hyperion DEFI also develops its owner -filled user (UFD) system which is designed to operate with a variety of topical ophthalmic liquids, including artificial tears and RECWET of lens. The project is particularly useful in chronic diseases on the front of the eye due to its improved ease of use, safety and tolerability and higher compliance potential compared to standard eye drops. Together, these advantages can cause compliance with higher treatment and better results for patients and providers.
For more information, please visit Hyperionefi.com.
Front instructions
With the exception of historical information, all the declarations, expectations and hypotheses contained in this press release are prospective declarations. Prospective declarations include, without limiting our approved products. These declarations are based on current expectations, estimates and projections concerning our company, in part, on the hypotheses made by management. These declarations are not guarantees of future performance and imply risks, uncertainties and hypotheses that are difficult to predict. Consequently, the real results and the results can, and in some cases, are likely to differ significantly from what is expressed or provided in prospective declarations due to many factors discussed from time to time in documents that we deposit with the Securities and Exchange American Commission.
In addition, such declarations could be affected by the risks and uncertainties linked, among others: the risks of our clinical trials, including, but without limiting themselves, the potential advantages of our products and the technology of the platform; the rate and degree of acceptance of the market and the clinical utility of our products; Our estimates concerning the potential market opportunity of our products; depended on third parties to develop and market our products; the ability of us and our partners to develop, implement and maintain manufacturing, marketing and marketing and strategies for our products; risks of intellectual property; Changes in legal, regulatory, legislative and geopolitical environments on the markets in which we operate and the impact of these changes on our ability to obtain the regulatory approval of our products and candidate products; our competitive position; Our ability to collect additional funds to maintain our commercial operations and make payments on our debt obligations as necessary; And the risks of our cryptocurrency strategy as detailed in our current report on the 8-K form filed on June 27, 2025.
All prospective declarations only speak on the date on which they are made, and unless it may be required under the laws applicable on securities, Hyperion DEFI does not have any obligation to update prospective declarations.
